Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Murali Janakiram, Carlyn Rose Tan, Rakesh Popat, Joaquín Martínez Lopez, Efstathios Kastritis, Chris Lau, Wee-Joo Chng, Prashant Kapoor, Hira Mian, Susan Bal, Ajay K. Nooka, Andre De Menezes Silva Corraes, Magdalena Corona, Arnab Chowdhury, Yi Lin, Thomas G Martin, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2024-211167

Published: 2024

Journal Articles

Longitudinal Trajectories of Patient-Reported Outcomes Among Older Adults with Multiple Myeloma (MM) Following Autologous Stem Cell Transplantation (ASCT)

Victoria Badia, Apoorva Doshi, Gayathri Ravi, Susan Bal, Kelly Godby, Donna Murdaugh, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri

Blood (2024) 144 (Supplement 1): 2387.

https://doi.org/10.1182/blood-2024-205712

Published: 2024

Journal Articles

Real World Evidence on Patient Reported Outcomes Among Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Regimens in Frontline (1L)

Smith Giri, Liton Francisco, Nicole Rafalko, Niodita Gupta-Werner, Joshua Richman, Smita Bhatia, Kelly Godby, Gayathri Ravi, Susan Bal, Marjohn Armoon, Rohan Medhekar, Luciano J. Costa

Blood (2024) 144 (Supplement 1): 5151.

https://doi.org/10.1182/blood-2024-203431

Published: 2024

Journal Articles

Decisional Regret Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Apoorva Doshi, Gayathri Ravi, Kelly Godby, Susan Bal, Victoria Badia, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri

Blood (2024) 144 (Supplement 1): 3767.

https://doi.org/10.1182/blood-2024-201735

Published: 2024

Journal Articles

BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Susan Bal, Myo Htut, Jesús G. Berdeja, Larry D Anderson, Jr., Adriana Rossi, Tara Gregory, Thomas G Martin, Luciano J. Costa, Hongxiang Hu, Jinjie Chen, Chaoqun Mei, Naomey Sarkis, Alok Shrestha, Safiyyah Ziyad, Wei-Ming Kao, Allison J Kaeding, Michael R. Burgess, Omar Nadeem

Blood (2024) 144 (Supplement 1): 2069.

https://doi.org/10.1182/blood-2024-203279

Published: 2024

Journal Articles

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Mayur S. Narkhede, Antonio Di Stasi, Lauren Kelly Shea, Susan Bal, Gayathri Ravi, Gaurav Goyal, Pamela Hardwick, Smith Giri, Donna Salzman, Ravi Bhatia, Luciano J. Costa, Amitkumar Mehta

Blood (2024) 144 (Supplement 1): 3449.

https://doi.org/10.1182/blood-2024-205205

Published: 2024

Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Blood (2024) 144 (Supplement 1): 2000.1.

https://doi.org/10.1182/blood-2024-200210

Published: 2024

Journal Articles

Optimal MRD-Based Endpoint in the Setting of Upfront Quadruplets (QUADs) to Support Response-Adapted Treatment Cessation in Newly Diagnosed Multiple Myeloma (NDMM)

Smith Giri, Binod Dhakal, Natalie Callander, Eva Medvedova, Kelly Godby, Susan Bal, Gayathri Ravi, Saurabh Chhabra, Rebecca W. Silbermann, Luciano J. Costa

Blood (2024) 144 (Supplement 1): 257.

https://doi.org/10.1182/blood-2024-205611

Published: 2024

Journal Articles

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 922.

https://doi.org/10.1182/blood-2024-201356

Published: 2024

Journal Articles

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2024-201755

Published: 2024

Journal Articles

Feasibility and Accuracy of Bioelectric Impedance Analysis in Estimating Skeletal Muscle Mass in Older Adults with Multiple Myeloma

Apoorva Doshi, Abigail Tucker, Gayathri Ravi, Susan Bal, Kelly Godby, William Evans, Mahalakshmi Shubha Shankaran, Luciano J. Costa, Grant Williams, Smita Bhatia, Smith Giri

Blood (2024) 144 (Supplement 1): 6963.

https://doi.org/10.1182/blood-2024-201688

Published: 2024

Journal Articles

Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation

Luciano J. Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai Dholaria, Smith Giri, Saurabh Chhabra, Susan Bal, Kelly Godby, Gayathri Ravi, Rebecca W. Silbermann, Natalie Callander

Blood (2024) 144 (Supplement 1): 363.

https://doi.org/10.1182/blood-2024-201914

Published: 2024

Journal Articles

Factors Associated with Post-Transplant Complications Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Apoorva Doshi, Gayathri Ravi, Susan Bal, Supriya Maheshwari, Kelly Godby, Luciano J. Costa, Joshua Richman, Grant Williams, Smita Bhatia, Smith Giri

Blood (2024) 144 (Supplement 1): 5145.

https://doi.org/10.1182/blood-2024-201737

Published: 2024

Journal Articles

Hospital Associated Disability Among Older Adults with Plasma Cell Disorders Receiving Autologous Stem Cell Transplant

Kyle Kidwell, Rui Zhu, Susan Bal, Kelly Godby, Gayathri Ravi, Luciano Costa, Sadeep Shrestha, Grant Williams, Smita Bhatia, Smith Giri

Blood (2023) 142 (Supplement 1): 3784.

https://doi.org/10.1182/blood-2023-189205

Published: 2023

Journal Articles

Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed By Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy

Tylan Magnusson, Luciano Costa, Smith Giri, Gayathri Ravi, Kelly Godby, Binod Dhakal, Bhagirathbhai Dholaria, Eva Medvedova, Natalie S. Callander, JoAnn Steele, Kathy Langley, Baylie Mullinax, Melissa Sentell, Stephen Horn, Candace Hill, Megan Boullion, Susan Bal

Blood (2023) 142 (Supplement 1): 2214.

https://doi.org/10.1182/blood-2023-187343

Published: 2023

Journal Articles

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 219.

https://doi.org/10.1182/blood-2023-181857

Published: 2023

Journal Articles

Immune Profiling of Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Induction and Autologous Stem Cell Transplantation (ASCT) and Comparison with Achievement of Minimal Residual Disease (MRD) Negativity

Susan Bal, Esther Zumaquero, Gayathri Ravi, Kelly Godby, Smith Giri, Ashley Denslow, Joaquin Bauta Perez, Fen Zhou, Suki Chen, Megan Padilla, Amna Siddiqui, Clare Ubersax, Erin Hornsby, Luciano Costa, Frances E Lund

Blood (2023) 142 (Supplement 1): 4685.

https://doi.org/10.1182/blood-2023-187551

Published: 2023

Journal Articles

Neurocognitive Performance Changes with Chimeric Antigen Receptor T-Cell Therapy in Patients with Hematologic Malignancies

Smith Giri, Smith Giri, Clare Ubersax, Abigail Tucker, Susan Bal, Kelly Godby, Luciano Costa, Smita Bhatia, Grant Williams, Gayathri Ravi, Mayur Narkhede, Donna Murdaugh

Blood (2023) 142 (Supplement 1): 5165.

https://doi.org/10.1182/blood-2023-189872

Published: 2023

Journal Articles

Outcomes of Patients with Newly Diagnosed Multiple Myeloma Experiencing Treatment Failure after Upfront Quadruplet Therapy and Autologous Stem Cell Transplantationgayathri Ravi 1 , Susan Bal 1 , Kelly Godby 1 , Smith Giri 1 , Clare Ubersax 1 , Abigail Tucker 1 , Luciano J Costa 1

Gayathri Ravi, Susan Bal, Kelly Godby, Smith Giri, Clare Ubersax, Abigail Tucker, Luciano Costa

Blood (2023) 142 (Supplement 1): 1989.

https://doi.org/10.1182/blood-2023-188272

Published: 2023

Journal Articles

Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM)

Binod Dhakal, Meera Mohan, Ravi Narra, Katie Palen, Aniko Szabo, Tyce Kearl, Gayathri Ravi, Susan Bal, Bryon D. Johnson, Marcelo Pasquini, Anita D'Souza, Parameswaran N. Hari, Luciano Costa

Blood (2023) 142 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2023-181266

Published: 2023

NARROW

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Longitudinal Trajectories of Patient-Reported Outcomes Among Older Adults with Multiple Myeloma (MM) Following Autologous Stem Cell Transplantation (ASCT)

Real World Evidence on Patient Reported Outcomes Among Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Regimens in Frontline (1L)

Decisional Regret Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Optimal MRD-Based Endpoint in the Setting of Upfront Quadruplets (QUADs) to Support Response-Adapted Treatment Cessation in Newly Diagnosed Multiple Myeloma (NDMM)

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Feasibility and Accuracy of Bioelectric Impedance Analysis in Estimating Skeletal Muscle Mass in Older Adults with Multiple Myeloma

Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation

Factors Associated with Post-Transplant Complications Among Older Adults with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation

Hospital Associated Disability Among Older Adults with Plasma Cell Disorders Receiving Autologous Stem Cell Transplant

Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed By Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Immune Profiling of Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Induction and Autologous Stem Cell Transplantation (ASCT) and Comparison with Achievement of Minimal Residual Disease (MRD) Negativity

Neurocognitive Performance Changes with Chimeric Antigen Receptor T-Cell Therapy in Patients with Hematologic Malignancies

Outcomes of Patients with Newly Diagnosed Multiple Myeloma Experiencing Treatment Failure after Upfront Quadruplet Therapy and Autologous Stem Cell Transplantationgayathri Ravi 1 , Susan Bal 1 , Kelly Godby 1 , Smith Giri 1 , Clare Ubersax 1 , Abigail Tucker 1 , Luciano J Costa 1

Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only